Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares gapped down prior to trading on Monday . The stock had previously closed at $25.05, but opened at $23.28. Ascentage Pharma Group International shares last traded at $23.28, with a volume of 167 shares traded.

Analysts Set New Price Targets

Several research firms have weighed in on AAPG. Oppenheimer started coverage on Ascentage Pharma Group International in a report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 target price on the stock. Piper Sandler started coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 target price for the company. BTIG Research began coverage on shares of Ascentage Pharma Group International in a research report on Monday, November 10th. They issued a “buy” rating and a $50.00 price target on the stock. Rodman & Renshaw began coverage on Ascentage Pharma Group International in a research report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price objective for the company. Finally, Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $48.40.

Ascentage Pharma Group International Trading Down 4.6%

The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54. The company has a 50-day moving average of $25.74 and a 200-day moving average of $32.56.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several large investors have recently made changes to their positions in AAPG. UBS Group AG lifted its stake in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares in the last quarter. XY Capital Ltd grew its position in Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares in the last quarter. Tema Etfs LLC acquired a new position in Ascentage Pharma Group International during the second quarter valued at $610,000. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International in the 2nd quarter worth about $391,000. Finally, Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International during the 3rd quarter worth about $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.